Previous 10 | Next 10 |
2024-03-26 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for STRO on March 26, 2024 06:07AM ET. The previous analyst recommendation was Buy. STRO was trading at $3.27 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
2024-03-26 02:02:34 ET More on Sutro Biopharma Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma Financial information for Sutro Biopharma ...
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling anti-leukemic activity of luvelta in pediatric patients with relapsed/refractory CB...
2024-02-01 17:56:16 ET Gainers: Meta Platforms ( META ) +14% . Amazon ( AMZN ) +8% . Codexis ( CDXS ) +5% . Sutro Biopharma ( STRO ) +5% . Kulicke and Soffa Industries ( KLIC ) +5% . Losers: Atlassian Corporation ( TEAM...
2024-01-04 16:19:31 ET Gainers: Molecular Partners ( MOLN ) +14% . Sutro Biopharma ( STRO ) +9% . Ribbon Communications ( RBBN ) +7% . Resources Connection ( RGP ) +7% . Pyxis Oncology ( PYXS ) +6% . Losers: 89bio ( ETN...
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients, including addressing unmet need in patients with low-medium FolRα expression P...
2023-12-29 16:11:47 ET Summary Positive results achieved from phase 1 dose expansion study using luveltamab tazevibulin for the treatment of patients with FRa-positive endometrial cancer. Phase 1 dose expansion study, using luveltamab tazevibulin in FRa-positive endometrial cancer...
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor webcast to highlig...
– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in combination – – Luvelta was generally well-tolerated – ...
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will ...
News, Short Squeeze, Breakout and More Instantly...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...
2024-04-03 17:00:02 ET Jay Olson from Oppenheimer issued a price target of $10.00 for STRO on 2024-04-03 14:01:00. The adjusted price target was set to $10.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $14.50 wit...